Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Ajinomoto Bio-Pharma","sponsor":"Humanigen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ajinomoto Bio-Pharma Services Signs Manufacturing Agreement with Humanigen for Lenzilumab","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Ajinomoto Bio-Pharma"}]

Ajinomoto Bio-Pharma

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Ajinomoto Bio-Pharma Services Signs Manufacturing Agreement with Humanigen for Lenzilumab

Details:

Aji Bio Pharma will provide drug product aseptic fill finish services for Humanigen. Lenzilumab, Humanigen’s Humaneered® anti-human granulocyte macrophage-colony stimulating factor monoclonal antibody is being administered as part of a Phase III study for COVID-19 patients.

Lead Product(s): Lenzilumab

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Humanigen

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement May 27, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY